Innate Pharma SA (IPH) Stock Statistics & Valuation Metrics

Innate Pharma SA has a market cap or net worth of €136.28M. The enterprise value is €95.26M.

Innate Pharma SA has 83.83M shares outstanding. The number of shares has decreased by -2.65% in one year.

Innate Pharma SA’s return on equity (ROE) is -0.15 and return on invested capital (ROIC) is -8.25%.

The current PE Ratio of Innate Pharma SA is -27.85. Innate Pharma SA’s PEG ratio is 0.30.

In the last 12 months, Innate Pharma SA had revenue of €44.51M and earned -€38.70M in profits. Earnings per share was -€0.49.

In the last 12 months, operating cash flow was -€28.60M and capital expenditures -€346.00K, giving a free cash flow of -€28.95M billion.

Innate Pharma SA pays an annual dividend of , resulting in a dividend yield of

Innate Pharma SA upcoming earnings date is Sep 17, 2025, Before Open.

Innate Pharma SA as a current ratio of 3.73, with Debt / Equity ratio of 0.77

In the past 12 months, Innate Pharma SA has paid -€9.75M in taxes.

Innate Pharma SA EV to EBITDA ratio is -23.76, with an EV/FCF ratio of -5.16.

Innate Pharma SA has €91.80M in cash and marketable securities with €35.50M in debt, giving a net cash position of -€56.30M billion.

Gross margin is -7.94%, with operating margin of -24.41%, and net profit margin of -14.59%.

The average price target for Innate Pharma SA is €4.38, which is 11.43% higher than the current price. The consensus rating is Moderate Buy